Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Grattan, Woodson"'
Autor:
David W. Dempster, Valerie A Ruff, Robert R. Recker, Eileen R Gallagher, David A. Hanley, Grattan Woodson, Sudhaker D Rao, Neil Binkley, Michael A. Bolognese, Jahangir Alam, David L. Kendler, Hua Zhou, Christopher Recknor, Paul D. Miller, Robert Lindsay, E. Michael Lewiecki, Kathleen A. Taylor, Jacques P. Brown
Publikováno v:
Journal of Bone and Mineral Research. 31:1429-1439
Previously, we reported the effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone formation based on biochemical markers and bone histomorphometry of the cancellous envelope at month 6 in postmenopausal women with osteoporosis who particip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8b78ff3625b74027f79301b30a6deaf
https://doi.org/10.1002/jbmr.2804
https://doi.org/10.1002/jbmr.2804
Autor:
David L. Kendler, Grattan Woodson, Hua Zhou, Christopher Recknor, David W. Dempster, Robert R. Recker, Robert Lindsay, D. Sudhaker Rao, E. Michael Lewiecki, Kathleen A. Taylor, Michael A. Bolognese, Boris Janos, Valerie A Ruff, Paul D. Miller, Xiaohai Wan, Jacques P. Brown, Neil Binkley, David A. Hanley
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 97:2799-2808
Recent studies on the mechanism of action (MOA) of bone-active drugs have rekindled interest in how to present and interpret dynamic histomorphometric parameters of bone remodeling.We compared the effects of an established anabolic agent, teriparatid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3317498cd9ffb4c9893bcc068982350
https://doi.org/10.1210/jc.2012-1262
https://doi.org/10.1210/jc.2012-1262
Autor:
John Yates, Paul D. Miller, Barbara Mako, Mary E. Smith, Angelo A. Licata, Joanne Palmisano, Lixia Wang, Mary E. Melton, Grattan Woodson, Mark P. Ettinger
Publikováno v:
Clinical Therapeutics. 22:1433-1442
Background: There have been reports from physicians in clinical practice that up to 30% of patients taking bisphosphonate therapy develop upper gastrointestinal (UGI) symptoms, many or most of which they assume to be related to the drug. However, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f485ca130f4316214321e9e24875a205
https://doi.org/10.1016/s0149-2918(00)83042-8
https://doi.org/10.1016/s0149-2918(00)83042-8
Autor:
Paul D, Miller, Gary, Hattersley, Bente Juel, Riis, Gregory C, Williams, Edith, Lau, Luis Augusto, Russo, Peter, Alexandersen, Cristiano A F, Zerbini, Ming-yi, Hu, Alan G, Harris, Lorraine A, Fitzpatrick, Felicia, Cosman, Claus, Christiansen, Grattan, Woodson
Publikováno v:
JAMA. 316:722
Importance Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. Objective To determine the efficacy and safety of abaloparatide, 80 μg, vs placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba920d78781a75d4ba28696c4b90ba6f
https://doi.org/10.1001/jama.2016.11136
https://doi.org/10.1001/jama.2016.11136
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 78:968-972
The purpose of this study was to examine bone histomorphometry before and after 2 yr of a double blind trial of etidronate to determine whether etidronate was associated with the development of osteomalacia and to clarify the mechanism of action. Six
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c3f00c0c9e7e46d49be28ab9cbbdba
https://doi.org/10.1210/jcem.78.4.8157728
https://doi.org/10.1210/jcem.78.4.8157728
Autor:
Stefan Goemaere, Andrea Wang, Christopher Recknor, Maria Luisa Brandi, Chui Kin Yuen, Michael A. Bolognese, Sigtas Stonkus, Grattan Woodson, Edward Franek, Arne Hoiseth, David L. Kendler, Cesar Libanati, Jose R. Zanchetta, Michael R. McClung, Jacques P. Brown
Publikováno v:
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 16(2)
FREEDOM was a phase 3 trial in 7808 women aged 60–90 yr with postmenopausal osteoporosis. Subjects received placebo or 60 mg denosumab subcutaneously every 6 mo for 3 yr in addition to daily calcium and vitamin D. Denosumab significantly decreased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3b20beb41ce352c4655c075b64a1301
https://pubmed.ncbi.nlm.nih.gov/22572531
https://pubmed.ncbi.nlm.nih.gov/22572531
Autor:
Javier San Martin, Ian R. Reid, Astrid Fahrleitner-Pammer, Rachel B. Wagman, Katre Maasalu, Henry G. Bone, Paul D. Miller, Grattan Woodson, Ivo Valter, David L. Kendler, Beiying Ding, Michael A. Bolognese, Jacques P. Brown, Michael S. Ominsky, David W. Dempster
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 25(10)
Denosumab, a human monoclonal antibody against RANKL, reversibly inhibits osteoclast-mediated bone resorption and has been developed for use in osteoporosis. Its effects on bone histomorphometry have not been described previously. Iliac crest bone bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243ea0094ea18b78c52eb723bee8edcd
https://pubmed.ncbi.nlm.nih.gov/20533525
https://pubmed.ncbi.nlm.nih.gov/20533525
Autor:
Richard M. Scheffler, Thomas H. Lee, Alan Hartstein, Allan H. Goroll, Grattan Woodson, Barbara Starfield, Walter Morris, Thomas Bodenheimer, Katharine Treadway, Paul A. Lombardo
Publikováno v:
The New England journal of medicine. 359(25)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231cea3861500d6a0c35fbcbe0b62e4c
https://pubmed.ncbi.nlm.nih.gov/19005194
https://pubmed.ncbi.nlm.nih.gov/19005194
Autor:
Hans Christian Hoeck, Arkadi Chines, Paul D. Miller, Claus Christiansen, David L. Kendler, Ginger D. Constantine, E. Michael Lewiecki, Amy B. Levine, Pierre D. Delmas, Grattan Woodson
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 23(4)
Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD. Introducti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603ccdcb9695a647eb659de93802e25a
https://pubmed.ncbi.nlm.nih.gov/18072873
https://pubmed.ncbi.nlm.nih.gov/18072873
Autor:
Grattan Woodson
Publikováno v:
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 3(4)
T-score discordance is observed when the difference between the hip and spine are sufficient to result in the two measurement sites falling into two different diagnoses as defined by the World Health Organization (WHO) classification system. This art
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3713095d66b3efc6e94cccfbe6bbe1f5
https://pubmed.ncbi.nlm.nih.gov/11175911
https://pubmed.ncbi.nlm.nih.gov/11175911